Clinical Trial Authorisation: A Final Look Back to Better Appraise the New European Regulation.

Clinical trials European regulation access to innovation authorisation indicators regulatory science

Journal

Reviews on recent clinical trials
ISSN: 1876-1038
Titre abrégé: Rev Recent Clin Trials
Pays: United Arab Emirates
ID NLM: 101270873

Informations de publication

Date de publication:
2023
Historique:
received: 12 10 2022
revised: 18 01 2023
accepted: 26 01 2023
medline: 28 8 2023
pubmed: 25 3 2023
entrez: 24 3 2023
Statut: ppublish

Résumé

The implementation of the new European Clinical Trial Regulation on 31 January 2022, is a major step to promote clinical research in Europe. The French National Agency for Medicines and Health Products Safety (ANSM) proposes to share some key aspects of the preparation for the application of the Regulation initiated in 2017 and to discuss shared indicators that should be considered to monitor clinical trials opportunities on a territory with regards to access to innovation for patients and attractiveness for sponsors. New criteria based on the time from the first request for authorisation to the first inclusion could be of particular interest to appraise the implementation of the European Clinical Trial Regulation.

Identifiants

pubmed: 36959158
pii: RRCT-EPUB-130250
doi: 10.2174/1574887118666230320124012
pmc: PMC10514496
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

167-171

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Références

Curr Rev Clin Exp Pharmacol. 2022;17(2):114-121
pubmed: 34455953
BMJ Open. 2017 Jul 10;7(7):e015579
pubmed: 28698332
Int J Breast Cancer. 2011;2011:831605
pubmed: 22295234
Sci Eng Ethics. 2016 Apr;22(2):451-66
pubmed: 26037896
Ann Oncol. 2019 Nov 1;30(11):1694-1696
pubmed: 31501860
Value Health. 2021 Dec;24(12):1773-1783
pubmed: 34838275
Health Econ Rev. 2022 Jan 3;12(1):1
pubmed: 34981266
Front Pharmacol. 2022 Aug 15;13:972660
pubmed: 36046816
Lancet. 2016 Jan 23;387(10016):326
pubmed: 26842439

Auteurs

Stéphane Vignot (S)

Agence Nationale de Sécurité du Médicament et des Produits de Santé, Boulevard Anatole France, 93200, Saint Denis, Grand Paris, France.

Gaelle Guyader (G)

Agence Nationale de Sécurité du Médicament et des Produits de Santé, Boulevard Anatole France, 93200, Saint Denis, Grand Paris, France.

Valérie Salomon (V)

Agence Nationale de Sécurité du Médicament et des Produits de Santé, Boulevard Anatole France, 93200, Saint Denis, Grand Paris, France.

Philippe Vella (P)

Agence Nationale de Sécurité du Médicament et des Produits de Santé, Boulevard Anatole France, 93200, Saint Denis, Grand Paris, France.

Isabelle Yoldjian (I)

Agence Nationale de Sécurité du Médicament et des Produits de Santé, Boulevard Anatole France, 93200, Saint Denis, Grand Paris, France.

Patrick Maison (P)

Agence Nationale de Sécurité du Médicament et des Produits de Santé, Boulevard Anatole France, 93200, Saint Denis, Grand Paris, France.

Christelle Ratignier-Carbonneil (C)

Agence Nationale de Sécurité du Médicament et des Produits de Santé, Boulevard Anatole France, 93200, Saint Denis, Grand Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH